Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Florida
great post and what's not to like about any of that? Ygen will do great between now and next spring, then even better as the lock down measure evaporate.
We are ina great position.
The Research Use Only" version of Clarigene™ SARS-CoV-2 first came on to the scene in June 2020 and could only be distributed to the professional services market. Open market distribution only came when Clarigene™ SARS-CoV-2 was given the full clearance and CE mark on 3rd August. Figures announced today are up to the end of September. That's two months trading for a new product that has already reached full capacity (10,000), not bad really I'm sure you will agree. Preparation and development for 20,000 per month expanded capacity will, in my view, take a little longer to establish as we cannot be exactly sure how this will be implemented. I can only assume the new CQC'd building would play some role bringing full capacity on stream by January as stated.
It has been widely acknowledged in the media that many products and services including major operations have been put on hold giving presedence to Covid care. In the wake of this fundamental change our core products are still expanding at the same rate as previous years - UK up 40%, Europe 80%, fulfilling market expectations (no slowing there). This expansion into Europe is carried against the so called headwind of underused products. This sees the expansion as an even more powerful force. However, many international markets including US and Japan also restricting standard use of care, have in addition prevented any sales penetration due to Covid. So if they can't get their products through, it's certainly not due to the companies failure, product fault or some financial impediment. The company is without doubt financially sound, so they don't need to push any harder on the core business front, just need to maintain Covid expansion. I fully expect the speedier tests now coming onto market will eventually have a dramatic impact on the control of Covid spread regardless of any Vaccine. This will in turn allow countries to lift restrictions in all areas allowing us open and rapid penetration. The only thing investors need to do now is wait for the full Covid update in December that should give a full rate of expansion and may still include Break-even. It's important to realise product segments like Molecular Genetics, already 75% up on last year will produce additional profit that will help to break down that £2.4m required to achieve Break-even. What we hope is that Covid sales and IONA nx expansion will provide the balance. All looks good to me.